Avoid common mistakes on your manuscript.
Past
Colorectal cancer (CRC) ranks among the most commonly diagnosed cancers worldwide.1 More than 5% of patients with CRC present with synchronous peritoneal metastases (PMCRC).2 In the Netherlands, select patients with isolated and limited PMCRC are treated with curative intent cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC).3 This treatment is exclusively performed at specialized HIPEC centers, while isolated PMCRC are diagnosed in all Dutch hospitals. However, a previous study showed that between 2009 and 2015 significant disparities in the odds of receiving CRS-HIPEC, and subsequently survival, existed on the basis of the hospital of diagnosis being either a specialized HIPEC center or a referring hospital.4 This resulted in patients possibly missing out on curative or life-prolonging treatment. To reduce this unintended variation between hospitals of diagnosis, national efforts were launched, including education on PMCRC, the inclusion of CRS-HIPEC in guidelines, the establishment of a national multidisciplinary working group (the Dutch Peritoneal Oncology Group, DPOG), initiation of nationwide prospective studies, and the enhancement of referral networks.
Present
Using real-world data, the present nationwide observational cohort study in patients with isolated synchronous PMCRC assessed the association between hospital of diagnosis (HIPEC center versus referring hospital) and the probability of undergoing CRS-HIPEC, and subsequent survival in the periods before (2009–2015) and after (2016–2021) aforementioned national efforts were initiated. Overall, the percentage of patients undergoing CRS-HIPEC increased from 17.2% in the first period (2009–2015) to 23.4% in the latter period (2016–2021). In the first period, patients diagnosed in HIPEC centers had a significantly higher odds of undergoing CRS-HIPEC [adjusted odds ratio (OR) 1.64, 95% confidence interval (CI) 1.02–2.67] and better survival [adjusted hazard ratio (HR) 0.80, 95% CI 0.66–0.96] compared with patients from referring centers. However, in the latter period, the differences in odds of undergoing CRS-HIPEC (OR 1.27, 95% CI 0.76–2.13) and survival (HR 0.80, 95% CI 0.66–0.96) were no longer statistically significant.5 These data suggest that national efforts initiated to reduce unintended interhospital variation may thus have contributed to equal access to care and a similar chance of survival for patients diagnosed with isolated synchronous colorectal PMCRC at a national level.
Future
The likelihood of receiving a specific treatment should not depend on the hospital of diagnosis, as this may result in patients being deprived of potentially curative or life-prolonging treatments. The results of the present study do not only underscore the importance of observational population-based data to recognize and rectify treatment and survival discrepancies between hospitals within a region or country, but also show that national efforts can make a difference in reducing unwarranted inter-hospital variation in access to care. These findings could provide an example for other countries and fields aiming to minimize disparities in medical practices between hospitals on a broader scale, thereby potentially improving access to optimal treatment and chance of survival for every patient.
References
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
Lurvink RJ, Bakkers C, Rijken A, et al. Increase in the incidence of synchronous and metachronous peritoneal metastases in patients with colorectal cancer: A nationwide study. Eur J Surg Oncol. 2021;47(5):1026–33.
Steffen T, Eden J, Bijelic L, et al. Patient selection for hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer: Consensus on decision making among international experts. Clin Colorectal Cancer. 2020;19(4):277–84.
Rovers KP, Simkens GA, Vissers PA, et al. Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study. Eur J Cancer. 2017;75:132–40.
van der Ven RGFM, van den Heuvel TBM, Rovers KP, et al. Towards equal access to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and survival in patients with isolated colorectal peritoneal metastases: A nationwide population-based study. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15131-0.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
The authors declare no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This article refers to: van der Ven RGFM, van den Heuvel TBM, Rovers KP, et al. Towards equal access to cytoreductive surgery with hyperthermic intraperitoneal chemotherapy and survival in patients with isolated colorectal peritoneal metastases: a nationwide population-based study. Ann Surg Oncol. (2024). https://doi.org/10.1245/s10434-024-15131-0.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
van der Ven, R.G.F.M., van den Heuvel, T.B.M., Rovers, K.P.B. et al. ASO Author Reflections: Addressing Hospital-Based Disparities in Access to Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) and Survival in Patients with Isolated Colorectal Peritoneal Metastases. Ann Surg Oncol 31, 3787–3788 (2024). https://doi.org/10.1245/s10434-024-15193-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-024-15193-0